KRRO
NASDAQ HealthcareKorro Bio, Inc. - Common Stock
Biotechnology
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $11.00 |
|---|---|
| 成交量 | 156,583 |
| 市值 | 158.65M |
| 贝塔系数 | 2.230 |
| RSI（14日） | 48.8 |
| 200日均线 | $18.29 |
| 50日均线 | $12.40 |
| 52周最高 | $55.89 |
| 52周最低 | $5.20 |
| Forward P/E | -2.18 |
| Price / Book | 1.33 |
🎯 投资策略评分
KRRO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (96/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 KRRO in your text
粘贴任何文章、记录或帖子 — 工具将提取 KRRO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.